HRP20070435A9 - Tricyclic-nucleoside compounds for treating viral infections - Google Patents

Tricyclic-nucleoside compounds for treating viral infections

Info

Publication number
HRP20070435A9
HRP20070435A9 HR20070435A HRP20070435A HRP20070435A9 HR P20070435 A9 HRP20070435 A9 HR P20070435A9 HR 20070435 A HR20070435 A HR 20070435A HR P20070435 A HRP20070435 A HR P20070435A HR P20070435 A9 HRP20070435 A9 HR P20070435A9
Authority
HR
Croatia
Prior art keywords
viral infections
tricyclic
nucleoside compounds
treating viral
compounds
Prior art date
Application number
HR20070435A
Other languages
English (en)
Croatian (hr)
Inventor
D. Keicher Jesse
Don Roberts Christopher
Johannes Reinhard Liehr Sebastian
Zheng Xiaoling
Prhavc Marija
Kumar Rajwanshi Vivek
Original Assignee
Genelabs Technologies
Gilead Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Technologies, Gilead Sciences filed Critical Genelabs Technologies
Publication of HRP20070435A2 publication Critical patent/HRP20070435A2/xx
Publication of HRP20070435A9 publication Critical patent/HRP20070435A9/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20070435A 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections HRP20070435A9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65746305P 2005-02-28 2005-02-28
PCT/US2006/007132 WO2006093987A1 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections

Publications (2)

Publication Number Publication Date
HRP20070435A2 HRP20070435A2 (hr) 2008-02-29
HRP20070435A9 true HRP20070435A9 (en) 2008-09-30

Family

ID=36570903

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20070435A HRP20070435A9 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections
HR20070436A HRP20070436A2 (hr) 2005-02-28 2006-02-28 Triciklički nukleozidni predlijekovi za liječenjevirusnih infekcija

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20070436A HRP20070436A2 (hr) 2005-02-28 2006-02-28 Triciklički nukleozidni predlijekovi za liječenjevirusnih infekcija

Country Status (18)

Country Link
US (4) US7524825B2 (enExample)
EP (2) EP1853617A1 (enExample)
JP (2) JP2008531703A (enExample)
KR (2) KR20070106781A (enExample)
CN (2) CN101142226A (enExample)
AP (2) AP2007004128A0 (enExample)
AR (1) AR058419A1 (enExample)
AU (2) AU2006218704A1 (enExample)
BR (2) BRPI0607769A2 (enExample)
CA (2) CA2597683A1 (enExample)
EA (2) EA200701849A1 (enExample)
HR (2) HRP20070435A9 (enExample)
IL (2) IL184955A0 (enExample)
MX (2) MX2007010463A (enExample)
NO (2) NO20074613L (enExample)
TW (1) TW200640474A (enExample)
WO (2) WO2006093987A1 (enExample)
ZA (1) ZA200707410B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546055A (en) * 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
CA2597683A1 (en) * 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside prodrugs for treating viral infections
AR056327A1 (es) * 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
ATE525068T1 (de) 2007-02-28 2011-10-15 Conatus Pharmaceuticals Inc Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
GB0718575D0 (en) * 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
KR101620394B1 (ko) * 2008-04-03 2016-05-12 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
GB0900914D0 (en) * 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
CA2756815A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Peri-fused pyrazolo-pyrimidine compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
TWI498117B (zh) 2010-03-31 2015-09-01 Gilead Pharmasset Llc 核苷氨基磷酸酯
EP2609923B1 (en) 2010-03-31 2017-05-24 Gilead Pharmasset LLC Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
WO2011123586A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
KR20140064765A (ko) 2011-06-30 2014-05-28 스텔라 에이피에스 Hcv 조합 치료
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2639238A1 (en) * 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
US20130315868A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
CA2887578A1 (en) 2012-10-08 2014-04-17 Idenix Pharamaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
EP1304335B1 (en) * 1990-04-04 2009-06-10 Novartis Vaccines and Diagnostics, Inc. Hepatitis C virus protease
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2159639A1 (en) * 1993-04-02 1994-10-13 Vincent J. Miles Method for selective inactivation of viral replication
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
WO1997012033A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
US6030785A (en) * 1997-03-05 2000-02-29 University Of Washington Screening methods to identify agents that selectively inhibit hepatitis C virus replication
WO1998043991A1 (en) 1997-04-02 1998-10-08 Amersham Pharmacia Biotech Uk Limited Tricyclic base analogues
CA2312484A1 (en) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1355916B1 (en) 2001-01-22 2007-01-10 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003061385A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
EP2345658A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
US7144868B2 (en) * 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2005042556A1 (en) * 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2597683A1 (en) * 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside prodrugs for treating viral infections

Also Published As

Publication number Publication date
WO2006093987A1 (en) 2006-09-08
AR058419A1 (es) 2008-02-06
MX2007010463A (es) 2007-11-08
HRP20070435A2 (hr) 2008-02-29
US20090253648A1 (en) 2009-10-08
EP1853617A1 (en) 2007-11-14
MX2007010460A (es) 2007-11-08
US20060252715A1 (en) 2006-11-09
BRPI0607769A2 (pt) 2009-10-06
EA200701849A1 (ru) 2008-02-28
JP2008531703A (ja) 2008-08-14
JP2008531704A (ja) 2008-08-14
HRP20070436A2 (hr) 2008-02-29
BRPI0607770A2 (pt) 2009-06-13
CN101142226A (zh) 2008-03-12
KR20070106781A (ko) 2007-11-05
US20090208457A1 (en) 2009-08-20
IL184955A0 (en) 2007-12-03
AU2006218704A1 (en) 2006-09-08
NO20074915L (no) 2007-11-20
KR20070106767A (ko) 2007-11-05
AP2007004118A0 (en) 2007-08-31
US20060194749A1 (en) 2006-08-31
US7524825B2 (en) 2009-04-28
AP2007004128A0 (en) 2007-08-31
EA200701850A1 (ru) 2008-02-28
TW200640474A (en) 2006-12-01
CA2597685A1 (en) 2006-09-08
CN101128474A (zh) 2008-02-20
NO20074613L (no) 2007-11-27
ZA200707410B (en) 2008-10-29
AU2006218705A1 (en) 2006-09-08
US7534771B2 (en) 2009-05-19
IL184954A0 (en) 2007-12-03
WO2006093986A1 (en) 2006-09-08
EP1853618A1 (en) 2007-11-14
CA2597683A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
HRP20070435A9 (en) Tricyclic-nucleoside compounds for treating viral infections
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
CY1111423T1 (el) Αναστολεις ns5b hcv
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
EA201290993A1 (ru) Нуклеозидфосфорамидаты
EA200700243A1 (ru) Способы лечения гепатита с
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
EA200901241A1 (ru) Соединения для лечения гепатита с
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
EA201100390A1 (ru) Соединения для лечения гепатита с
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2008008907A3 (en) Antiviral agents
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
EA201000051A1 (ru) Противовирусные соединения, композиции и способы использования
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
EA201001835A1 (ru) Противовирусные соли
UY28580A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
MY142331A (en) Bicyclic heteroaryl derivatives for treating viruses

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A9IS Complete republication of an hr-a document
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081223

Year of fee payment: 4

OBST Application withdrawn